Latest / The Well Made Podcast / Will I Ever Feel Like Myself Again After Breast Cancer?
Transcript
- Brookes vaughan: Today's episode is with Dr. Corinne Minn, and I have been so excited to share this conversation with y'all. Dr. Minn is a board-certified OBGYN and Menopause Society certified practitioner whose practice focuses on menopause management, breast cancer survivorship, and caring for women at high risk for breast cancer. Through her telehealth practice, she provides Personalized consultations and education to help women navigate an area of medicine where so many have felt overlooked or underserved. What really makes her perspective especially meaningful is that she has lived this herself. She is a 25 year breast cancer survivor, a braca carrier, and someone who experienced premature menopause. She brings both the knowledge of a physician. And the understanding of a patient to the women that she serves. Beyond her clinical work, Dr. Min teaches continuing medical education courses and speaks at national conferences, including Harvard's Women's Health and Menopause Conference, where I personally and my team learned so much from her. She also serves on the Council of Advisors for the Young Survival Coalition and as a medical advisor and U.S. ambassador. For menopause and cancer. You may also know her on Instagram at Dr. MenobgyN, where she makes complex research approachable for women and healthcare providers alike. I am so grateful for her voice, her advocacy, and the experience she brings to this conversation. And honestly, I am just so honored to have had the opportunity to have this conversation with her. I hope this episode. Leaves you feeling more informed, encouraged, and equipped. And I really hope it blesses you. Let's get into it. first, before we kind of dive into the nitty-gritty, I was thinking about you interviewing you, and the word passion came to mind. And I love that the word passion comes from suffering. It means suffering when you look in, Dr. Corinne Menn: Mm-hmm. Brookes vaughan: even the biblical sense Dr. Corinne Menn: Agree. Brookes vaughan: and the root. And I see your passion for your patience. I see your passion for the work that you do. You obviously have the knowledge and the skill set and the training, but I think your passion probably also comes from your own suffering. Dr. Corinne Menn: Hmm, for sure. Brookes vaughan: I would love for you to talk a little bit, if you don't mind, about just what got Dr. Corinne Menn: Mm-hmm. Brookes vaughan: you here to take care of the patients that you see. You have such a heart for breast cancer survivors, previvors, women who are navigating Dr. Corinne Menn: Mm. Brookes vaughan: perimenopause and menopause. So what got you here? Dr. Corinne Menn: Well, first I want to say that I don't think you have to have gone through any one particular disease or challenge to be a compassionate, excellent physician or healthcare professional. but it's certainly, it's certainly added to my level of really my education and and does drive my passion and my mission. so experiencing not only Breast cancer as a young woman diagnosed at 28 and then plunged into temporary menopause two times and then a third time permanently with you know surgical menopause and really suffering with the collateral damages, not only from that premature menopause, but of course from the whole cancer, you know, treatment experience. But also at the heart of it, really, and I don't know if I talk about this enough, at the heart of it is not just that. I didn't feel I had the knowledge base as an OBGYN to help myself or others like me or even the average menopausal woman. But a lot of the root problems were that that my concerns weren't taken seriously, even asked about, and then I was dismissed and I actually ignored symptoms in myself. And so I think. I have not experienced every type of medical issue that can confront a woman, but it really gave me a different lens on viewing a patient, viewing my responsibility. And it really fired me up because when we dismiss, when we ignore, when we belittle, we don't even ask the questions. we're just hurting so many patients, right? And we're not, we're not living up to the standards, I think, of of what we should as as clinicians, as physicians. So yeah, so it it was a real it was education by fire, really. Brookes vaughan: Yeah. Dr. Corinne Menn: you know, going through OBGY and residency training while navigating a breast cancer diagnosis treatment, premature menopause, all on the heels of my mom, who had died of stage four ovarian cancer just a few months prior. And she had ignored her symptoms, written her symptoms off, her symptoms had been dismissed, and that's a whole nother story. But the commonality was that it was like my first lesson in patients not being taken seriously. And Brookes vaughan: Yeah. Dr. Corinne Menn: often because maybe we didn't have easy answers, right? We didn't have easy answers to how to treat my symptoms. We didn't have easy answers on how to deal with a young woman with breast cancer. But just because we don't have easy answers does not mean that we can just throw our hands up and be like, well, I'm sorry. Cause that's basically the message now. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: is that we don't have enough data in certain areas. So I'm sorry. Yeah. Brookes vaughan: Sorry. Yeah. You know, it's interesting that you say that. I think we we have an incredible Dr. Corinne Menn: Mm-hmm. Brookes vaughan: medical oncology team here. And then we have a large, you know, OBGYN base here in in Georgia and Athens. But it is kind of interesting because when you see a patient who has been diagnosed with breast cancer, the oncology team is wanting to save her life. And then the OB OBGYN team is kind of like, hands off, I can't do anything. And they're kind of lost in the phrase of okay, you also, yes, we want to save your life by reducing by, you know, ridding your cancer, preventing recurrence, but we also want to think about your brain, your heart, your bones, your mental health, your vaginal health. What would you say is if you were diagnosed with breast cancer today? if you're a a patient, you're newly diagnosed, what are things you would ask for, advocate for? Dr. Corinne Menn: Mm-hmm. Brookes vaughan: how would you approach a diagnosis now? Dr. Corinne Menn: It's very overwhelming because breast cancer, newly diagnosed breast and everything that we say about breast today applies. So anyone listening to other cancers, because cancers are on the rise in younger women, colon cancer, GYN cancers, etc. It's these same principles apply. So I never want those women to feel left out. it is overwhelming because when you first get diagnosed, there's so many decisions. Who's your surgeon, what's next, where are you gonna go for treatment, you know, meeting with different opinions, you know, all about just the treatment, right? But what I would say is you do, while those are the most important things you need, what's that next step for my treatment? I think you always have to keep in the back of your mind that survivorship starts on the very first day you're diagnosed. You are in Brookes vaughan: Mm-hmm. Dr. Corinne Menn: survivorship mode because you are are living to try to survive and thrive. So Brookes vaughan: Mm-hmm. Dr. Corinne Menn: you have to always think about like, okay, how how are the decisions that I make now, the treatments that are coming at me now? I'm going to impact my future. And that can seem overwhelming, but if you just break it down and always remember to ask that Brookes vaughan: Mm-hmm. Dr. Corinne Menn: as part of your questioning, and it can really apply to a lot of things, whether it's your surgery, we I don't talk enough about the impact of breast surgeries on women, sexual health, the loss of nipples, Brookes vaughan: Yeah. Dr. Corinne Menn: disfigurement, even just from lumpectomies, from radiation, the psychological health for you going forward. That was part of say why I chose. in the end, I wound up chosen choosing a bilateral mustache, because for me personally, not for everybody, that Brookes vaughan: Mm-hmm. Dr. Corinne Menn: was part of my long-term survivorship that I couldn't deal with the, the the intensive screening and the and the what ifs. That was very stressful for me, right? So you have Brookes vaughan: Mm-hmm. Dr. Corinne Menn: to think about you what are you doing now and how is it gonna impact the future? And people may take that from a different lens. Some people would feel maybe opposite to me on say the surgery thing. and so we talked. about that sometimes with patients but what we we often don't talk about what is going to be now the impact on my ovarian function and it doesn't matter whether you're young or you're in your you know perimenopausal like more middle-aged years or you're older and already through quote unquote menopause Brookes vaughan: Mm-hmm. Dr. Corinne Menn: all of the breast cancer treatments for the most part are are going to impact your hormones in some way even if you're not even if you're already in Natural menopause. because for instance, those medications like aromatase inhibitors, you know, take away any hormones that you did have and lower lower those estrogen levels at, you know, close to Brookes vaughan: Mm-hmm. Dr. Corinne Menn: zero. So I think always, always keeping that thread of how is this going to impact my future, whether it's fertility, my bone health, my heart, my mood, my sex, etc. And what can I do up front? Get a baseline. So I would I really think it's important when you're coming into breast cancer treatment, understanding this is a marathon and not a sprint. Let's shore up, let's take stock of where my health is now. And what things can I do, doctor, proactively, and ongoing that's gonna help me, and those things are as important as your cancer treatments, in in my opinion, because you can only be a successful. You can only have successful treatment if you can tolerate it, if you could weather it, if you could feel supported during it. And I think a lot of things Brookes vaughan: Mm-hmm. Dr. Corinne Menn: fall by the wayside in terms of of getting patients through treatment. Brookes vaughan: And when you're saying baseline, you mean baseline labs, Dr. Corinne Menn: Mm-hmm. Brookes vaughan: baseline DEXA screening, baseline yeah. Dr. Corinne Menn: That and also so it's yes. So I think you want to like say, like, okay, I'm about to, do something big, go through breast cancer treatment, whatever your treatment entails. It's a great time to, yes, get a basic assessment of where is your overall physical health, right? So certainly where are your lipids, get an enhanced lipid profile, get your baseline bone density. know your baseline risks based based on family history, your lifestyle, et cetera, for for cardio, metabolic, bone health, et cetera. That's super Brookes vaughan: Mm-hmm. Okay. Dr. Corinne Menn: important. But I also think it's important, and this does not get done, but to identify those women who might be particularly at risk for some of the side effects of that often abrupt ovarian hormone disruption. So examples, What I wish all women before they started chemotherapy or ovarian function suppression, tamoxifen or aromatase inhibitors or having their ovaries removed is did you have a past history of PMDD? Do you have controlled or stable Brookes vaughan: Yeah, yeah. Dr. Corinne Menn: anxiety or depression? Did you have postpartum depression? Are you somebody who found a lot of mood changes when maybe you're on the birth control pill in the past? Those Brookes vaughan: Mm-hmm. Dr. Corinne Menn: are questions that if someone answers multiple of those or at least one of those, I in my mind I'm like, hey, I'm gonna just prepare this woman that when she goes through hormone blocking, hormone changes, whatever, we have to inform her that she's maybe at an increased risk, at at having, mental health problems. that is like always overlooked, I find. And same and the same thing could go true with the heart stuff, right? So let's take stock of your own, like, you know, your labs and stuff, but how about like he? Did you have pre-eclampsia? Did you have preturn delivery? Did you have you have female-specific risk factors for cardiovascular disease? Last Brookes vaughan: Right. Dr. Corinne Menn: week I saw a couple of patients who had a long-standing history of endometriosis and they're going to be started on tamoxifen and they're really afraid of what that's going to do. And nobody asked them about their endometriosis. Or, you know, I've had patients where it really flared and it set down a cascade of other issues. So I think we have to better screen and take stock of these women who were were, were putting on long-term treatment. And what it I see it as an afterthought because everyone's focus on the surgery clearance and maybe getting through chemo, herseptin, some of the big gun Brookes vaughan: Mm-hmm. Dr. Corinne Menn: IV infusion immunotherapy treatments. And then they say you're no longer in active treatment, quote unquote. So they might move into the phase where they're on five to ten years. Of some type of hormone blocking, estrogen deprivation, and that's not considered active treatment. Well, to me, that felt as active as my Brookes vaughan: Absolutely. Dr. Corinne Menn: other stuff. And so sometimes the collateral damages, the side effects of that, I think are not taken as significantly. And that's when maybe your hair is growing back and you're trying to move on with your life. And even your friends and family around you are like, you beat this, you're doing great. And meanwhile, when I look back, those were some of my hardest years because I had so much fear of recurrence and and and I I was also struggling with totally unmitigated side effects of these medications with very little help because you remember 20, 25 years ago, menopause, premature menopause, half fleshes was not a hot topic. So I was like living in the dark ages of help, you know, but but Brookes vaughan: Yeah, for sure. Yeah. Dr. Corinne Menn: I see it still is persisting, Brookes vaughan: let's do case a case study. I'm thinking about a specific patient in our clinic Dr. Corinne Menn: Only. Brookes vaughan: right now who is 42 years old. She was diagnosed with stage one estrogen receptor, progesterone receptor positive breast cancer. when she was thirty Dr. Corinne Menn: Yeah. Brookes vaughan: nine, underwent, lumpectomy, not a double mastectomy, lumpectomy, chemotherapy, and is now doing monthly lupron injections. She's on year three of monthly lupron injections. Not she's not on anything else at this point, just lupron, and is miserable. And I put a little question box up recently and sh her question was, Will I ever feel like myself again post cancer on these medications? What how would you say you have a patient in your practice who's, you know Post the big guns. Now she's a few years out on an astrazole and what can you do for her? What would you say she could could do? Dr. Corinne Menn: So I one thing I always start with when I see patients with breast cancer treatment, side effects, menopause is I always want to take stock first of what was their cancer. I always ask for their pathology report. I always want to know the nitty-gritty details because sometimes I'm surprised women don't know all the details of their actual breast cancer diagnosis. They might know their stage, but they don't know some of the details. I think it's really important to try to assess. What is their risk of recurrence? What is their benefit from their current therapy? And it works on two ends. On one end, sometimes they have a woman who likes wants to quit, is really frustrated, and they don't actually realize maybe the full magnitude of benefit, both short term and long term, that they're getting from their endocrine therapy. So it's always important to let's take stock. What are you doing? Why are you doing this? What benefit are you getting from it? And what options do you have? And Yes, the medical oncologist should and generally does do those things, but I I find sometimes nuance is lost in the shuffle there. And I see it on both ends. I see some women who no one really explained to them that you know they're not getting a tremendous benefit from their current treatment. And you know, we may be talking about a few percentage points at the 10 or 15 year mark in risk recurrence reduction. And on the other hand, there are some patients who might have 10, 20 percent benefit. Like so we have to. not treat these breast cancer patients on say an aromatase inhibitor exactly the same. They're each different, even within a stage one, even within a stage one, they're different, right? Brookes vaughan: Mm, that's right. Dr. Corinne Menn: And so we have to think about that first. And then when they and many of them tell me exactly what you said. I don't feel like myself. I I want my life back. And so, you know, when they present and say that to their medical oncologist, that can seem overwhelming to a medical oncologist who's also taking care of lots of other cancer concerns, right? And treatment concerns. So you have to really, this is where I think a menopause specialist is really important because we can drill down and say, well, well, what do you mean you don't feel like yourself? And you know what it means for one woman may be different than the other. And so when we do a really complete intake inventory of her menopausal symptoms, her sexual health symptoms, her her ability to function in life, how it's impacting her work, her family, et cetera, a big picture. And then we sit back and normally it's pretty easy for me to see what are the the low-hanging fruit or the easy things to tackle. But I always pose to them, if I could help you with one to three of these things, what were the top three things that we could tackle now? So that's my overarching strategy. And I and I remind women that they always have choices. There's always choice within endocrine therapy. So endocrine therapy is not one size fits all. Sometimes I find patients are presented it as this is the true way and the only way. But there is something called individualizing endocrine therapy. I I have to say, I I think in general, it's not done that well. I think there's a lot of formulaic kind of knee-jerk, like this is what we do when, and my answer there is it's it's I The best endocrine therapy or the best adjuvant therapy for a woman is the one that she can tolerate, that she can complete. And if Brookes vaughan: Right. Dr. Corinne Menn: it's destroying your life here, it's okay to take a step back, right? So that's and so before I even get into all the solutions, which of course we can talk about today, we have to do those things kind of first, right? Brookes vaughan: Right. Dr. Corinne Menn: even deciding whether like extended therapy or not, because there's a big push for like. Do we do 10 years versus five years? Women are like, Well, that's what they told me. I'm like, Did anybody talk to you about a breast cancer index or how much actual Brookes vaughan: Mm-hmm. Dr. Corinne Menn: benefit you're gonna get from another five years? And if you really are gonna get a benefit from it and you're already struggling, well, we better, we we need to like pause and figure out how we can better support you. but as you can see, just me talking about that, that takes a lot of time, and that's not even with a patient's symptoms. So you can imagine when they get to the medical oncologist, and maybe their appointments slotted for 15 or 20 minutes. They're just as busy, those out the medical oncologists are just as busy as the OBGYNs and everybody else is. And so I actually think I'm starting to like make this call out that I think the the cancer centers are failing, the patients and the doctors, because it's very hard to give adequate care and support Brookes vaughan: Right. Dr. Corinne Menn: when they don't have the time. And they're I can't name a cancer center that I think truly has. An accessible, available menopausing cancer and sexual health clinic to support their medical oncologists. These cancer centers are making millions and millions of dollars. The fact that they don't have separate clinics that these doctors can refer patients to, patients Brookes vaughan: Right. Dr. Corinne Menn: have to scrap online and figure out a way to find it. So Brookes vaughan: Right. Dr. Corinne Menn: I think that's a big, big part of the problem because I Brookes vaughan: Mm-hmm. Dr. Corinne Menn: don't want it to become any of this messaging to vilify like. menopause doctor against the medical oncologist, against the primary care Brookes vaughan: Absolutely like. Dr. Corinne Menn: doctor. Actually we're all in this together and Brookes vaughan: Yes. Dr. Corinne Menn: we're all raising a five alarm fire that Brookes vaughan: Yeah. Dr. Corinne Menn: the current system is not working for women with cancer. It's just not. Yeah. Brookes vaughan: That's right. That's right. And I you've worked in a large, I'm sure at some point in your career, medical Dr. Corinne Menn: Yes. Brookes vaughan: healthcare system like I have. And when you have ten minutes and you're seeing 40 patients a day, I remember at the end of a week on Fridays, just my body just felt like it was coming down from all of this anxiety Dr. Corinne Menn: Yes. Brookes vaughan: of like I can't take care of these patients like I want to. And it's not the Nobody goes into oncology with ill will. They want to save lives. Dr. Corinne Menn: Mm-hmm. Brookes vaughan: They want to take care of their patients. It is, I think you're so right, the comprehensive care when you, especially with women, you're looking at them as a whole person. They just don't have the the time a lot of times to to do that. I'd love to talk a little bit about say you have a tamoxifen, a patient on tamoxifen. What is your approach there? Say she is miserable with menopausal symptoms. how do you navigate a conversation? And I know there's risk stratification and you're looking at the breast cancer index. How do you navigate when a patient might be a an appropriate candidate for some form of hormone replacement therapy versus Hey, we need to look at other options to help mitigate your your symptoms. I think that that's a really hard conversation that a lot of OBGYNs, women's health clinics are a little bit afraid to have because we Dr. Corinne Menn: Works. Brookes vaughan: never want to go against what a patient's oncologist is telling them, but we also are the ones sitting down with them hearing, hey, I'm struggling with these symptoms. They might not be, As important as saving my life and preventing a recurrence or getting rid of this cancer, but they're still very important. So how do you approach that conversation? And even maybe with a patient who potentially may be on something like anastrazol or luprona, hey, we might want to go back to your oncologist and have that conversation of is there another treatment option that would allow us to block estrogen receptors in your breast, but also give you some form of, you know, benefit from Dr. Corinne Menn: Yeah. Sure. of course, this is not personal medical advice and individualizing things, but when I look at a patient, I'm like, are you in the middle of active endocrine therapy? Yes or no. If you're in the middle of active endocrine therapy and you are really suffering, my very first question is, what you know, can we change your endocrine therapy? Can we do a paused planned therapy? drug holiday, which is completely underused. So we talk about drug holidays in the medical oncology world sometimes, they're switching between aromatase inhibitor saying, does one cause more joint pain than the other? So they'll take a drug holiday for two weeks and then we'll switch it. But to me, that's that's not what I'm talking about. I'm talking about you've got that woman in front of you. She feels broken. She's been through all of this. Then they put her on this like estrogen deprivation with no support and asked her to run a marathon, literally five, 10 years of this. Sometimes I say, I remind patients for the vast majority of early stage breast cancer patients, one, two, and even some stage threes, right? We allow them, we support them to pause for up to two years to get pregnant, to have IVF, to have babies. This is considered, you know, this is guideline supportive management for those women wanting to preserve fertility. So I use that as an example. You've had some patient who's maybe been on the endocrine therapy for a few years, really struggling. If for and fertility is let's put the fertility question aside. So you would allow her if she wanted to get pregnant to pause, regroup, do something that meant something for her. How about I propose, wonder if we do a planned pause to because you and I both see it, we know they come in, their genital urinary syndrome symptoms are horrific. The atrophy Brookes vaughan: Mm-hmm. Dr. Corinne Menn: is really bad because no one's given them any vaginal hormones. So Brookes vaughan: Mm-hmm. Dr. Corinne Menn: The pause will allow a little reprieve from the hormone suppression, allow some recovery, of course, with local vaginal hormones, but just, removing the medication itself helps that, right? Temporarily. And Brookes vaughan: Mm-hmm. Dr. Corinne Menn: then, but and then say their joint pain, say their insomnia has gone into a spiral and the mood and some and and they they can't exercise and they feel terrible. So I have helped patients work with their medical consciousness, say, like, we're doing a very directed, planned pause where We're, but it's not just gonna be random. It's like if you're doing this, then at the same time, you're gonna work with a trainer, you're gonna go see a pelvic or physiotherapist, we're gonna start vaginal hormones, we're gonna get you something non-hormonal for hot flashes and night sets. We've got some good new non hormonals. And then when you restart, maybe you restart at baby tamoxifen, half dose tamoxifen, you restart on a different AI, maybe you restart with full dose tamoxifen, whatever the case may be, or if you need to be on an aromatase inhibitor. because you have a real big benefit, then maybe we switch the one that you were on. we have options, right? but just doing what you're doing without changing anything is generally not going to be successful. So to me, that's something that is not used. And again, I'm not talking about for two years. I'm I'm saying like you could do this for a few months, regroup and reset. So that's something that I find is very underutilized. Then there are the patients who are like, I have tried this. I it I I cannot tolerate the rhombase number. I cannot tolerate the tamoxifen. And I I'm stopping that. Right. So sometimes then the next thing is, okay, if patients get to a point where they're stopping and patients make a choice, before we immediately introduce, like, should we use something systemic hormone? we always want to reassess like what how do they feel off? Because sometimes. Once they've taken the pause, they realize, like, okay, you know, I was desperate for HRT, but maybe I was just desperate for a break. And so we kind of regroup there. And then of course, the biggest question is when we have a patient who has either completed their endocrine therapy or you know, truly completed it, they did their five years or 10 years, whatever was asked of them, or they they tried and it's this is done. Like whatever happened, happened, and they are not going back on that. That's when we have that question of how do we make decisions about systemic hormone therapy? And, that is complicated. but I always quote back Dr. Linda Bosserman and Dr. Don Dizan wrote in the Journal of Clinical Oncology a great kind of clinical opinion piece called Personalization, not prohibition. And I think at that point in time, we have to start looking at women. fully autonomous human beings who are capable of making decisions for themselves. most breast cancer survivors are terrified, who are either positive or even, estrogen negative, they're terrified of recurrence. I know I live with that. And they take that recurrence risk very, very seriously. And so I think that's a time when we must take stock of what is your baseline recurrence risk now at five, 10 years. How does that recurrence risk trend for your type of breast cancer. And then it comes down to what do we know about hormone therapy after breast cancer, systemic hormone therapy after breast cancer. And I think it's very, very important that we be bluntly honest with patients that while there are reassuring observational data, there is some randomized controlled data that never met maturity, like you know, the Stockholm trial, the habits trial, These very long time ago randomized controlled studies looking at HRT after breast cancer had opposite signals. One showed a harm, one showed no harm. But the bottom line is neither reached maturity in terms of being really Brookes vaughan: Yeah. Dr. Corinne Menn: knowing whether their data was statistically significant. So we're kind of left with a big question mark. And so I think we have to kind of look at that individual person in front of you and say, if we gave you systemic estrogen. Theoretically, if you've got dormant breast cancer cells that get woken up, and just being exposed to estrogen is not necessarily what's going to wake them up. There's lots of things that can wake metastatic disease up. We don't actually know what wakes it up. That's what we're trying to figure out. And then we could cure stage four breast cancer. but you have to have a a, an intelligent conversation where they can accept a theoretical risk, and the risk is. I think the way I say it, the risk is proportional, likely, to your kind of disease burden, how big of your baseline risk to begin with. And if you have extremely low baseline risk, then you're, adding a very low dose of estrogen, a little bit of progesterone, if you have a uterus or sometimes even if you don't have a uterus. and then we could talk about testosterone kind of separately, Brookes vaughan: Yeah. Dr. Corinne Menn: is is I think, you know, kind of a reasonable thing that you get to decide. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: As a human being, about your life and how you're going to live. And it's really like there is no perfect data point that I can say, this proves that I'm right, that there is no risk. I don't think that's responsible to say, but I also can't say to the patient, I've got definitive evidence that we absolutely can't do this. And in fact, I would point out to a lot of things that might support that. It may be reasonable to consider it, right? a couple of mental exercise points that I often make is, and I'm sure you've seen patients like this, are women who had their breast cancer treatment, maybe went into a temporary menopause for whatever reason, whether it was chemo or their medications, but then that treatment ended, and then they went on to have five years, seven years, 10 years of menstrual periods. We see this a lot with triple negative patients. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: Who don't have estrogen receptor positivity, who might have temporary menopause from chemotherapy, but then their ovaries recover, right? If they're younger, and then they might go on to have 10 years. And then when they get to menopause, no one will talk to them about Brookes vaughan: Then we'll touch them. Dr. Corinne Menn: HRT. Or, or in BRCA carriers. So these are women who, whether they're triple negative or ER positive, had their breast cancer treatment. They may have had a return of ovarian function. They may have had a pregnancy or even two pregnancies. I've seen many of these types of patients. And then at some point they're like, okay, I'm taking my ovaries out to lower my risk of ovarian cancer. It's not to treat my breast cancer. And if I wasn't BRCA positive, I wouldn't be removing my ovarian function. And Brookes vaughan: That's right. Dr. Corinne Menn: in those cases, we we completely take off the table even having an intelligent conversation. So meaning the day before, it was okay for her to have circulating estradiol levels going from 30 to 400 or more. But then the next day, if I gave her a.0375 patch that maybe raised her blood level to 35 picograms per ml. Suddenly that's heresy, it just doesn't make sense, right? Brookes vaughan: Yeah, yeah. That makes sense. Mm-hmm. Dr. Corinne Menn: so I think we have to take stock of what has this patient already survived or been through from a hormonal exposure? Because I see a lot of those patients. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: and it just doesn't make any sense to me that we can't have an intelligent conversation about that. so I think that's super, super important. and then you alluded to it. I then I also think that systemic hormones, quote unquote, can mean a lot of different things. And that's where when we can be really knowledgeable and thoughtful about maybe what we're talking about, whether it would be a very low dose of estradiol, whether it would be premerin. Like I think it's an interesting thing to talk about. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: whether it would be a medication like Dew of V, which we're We can talk a little bit more about that because that's a an Brookes vaughan: Yes. Dr. Corinne Menn: estrogen combined with a CERM, a selective estrogen receptor modulator called basodoxifine. Brookes vaughan: Yeah. Mm-hmm. Dr. Corinne Menn: and it blocks estrogen receptors in the breast and it blocks estrogen receptors in the uterus. We just don't we don't have any data in a breast cancer survivor who maybe had metastatic breast cancer cells somewhere hiding out, right? But we can use the current available data to say, like, if you were going to start menopausal hormone therapy. maybe this is an interesting option. This is something we can talk about with shared decision making. Or if kind of sleep and anxiety and mood at, you know, at nighttime is a big issue, literally giving them 100 or 200 milligrams of progesterone at bedtime can literally be life changing for these women. And in the big picture, is that as quote unquote harmful of putting on the highest dose estrogen patch with the synthetic progestin? Brookes vaughan: Yeah. That's right. Dr. Corinne Menn: Probably not. Do I have a randomized controlled study to prove that? I do not. But we Brookes vaughan: Mm. Dr. Corinne Menn: can look at the available data there, right? And Brookes vaughan: Right. Dr. Corinne Menn: so I think we can't lose our minds and be like, my God, this is terrible to even bring up when we talk about systemic hormones, because hormones are different. so I know that was like a whole lot, but but Brookes vaughan: Yeah. So good. Dr. Corinne Menn: like that's kind of how I kind of like. how I have my conversations with my patients. Yeah. Brookes vaughan: Had that conversation. Mm-hmm. Mm-hmm. I'd love to go into the Duave, but talk to me about testosterone. Cause there's there's, you know, some emerging data on testosterone therapy. what what are you seeing? what are your thoughts on testosterone therapy with survivors? Dr. Corinne Menn: Yeah, it's a a big area of interest because, they're they're patients are asking because they're like, well, it's not estrogen. They're asking Brookes vaughan: Yeah. Dr. Corinne Menn: because they're hearing a lot about it and how maybe it has other benefits. and here's my take on it. and I think testosterone doesn't have to be this big scary thing. and I I think it's something that, We don't have a lot of data in breast cancer survivors, right? But a lot of our fears, concerns about testosterone, number one, my biggest concern is that someone's getting testosterone in very high levels like pellets, where their levels can go super high and get converted to estrogen. That's number one. So that's that's that would be my first like caution. I don't want you having high levels given to you. And the best way to avoid that is to avoid pellets, right? then I also want to like. We have I don't think we talk enough about that many of these breast cancer patients, not all of them, but many of them have lost their ovaries or have been exposed to, you know, gonadal toxic chemotherapy, right? So chemotherapies are toxic to your gonads, whether you're a male or female. So it reduces the output of the hormones coming from them. So, we that their their total secretion of, Testosterone androgens is going to be less. If they have their ovaries surgically removed, we've got very clear data that your amount of circulating androgens, testosterone is going to be at about 50% less, either a third to a half, right? And so, lowering their testosterone levels was not part of their breast cancer treatment. And we have to take seriously that impact. And of course, we don't take it seriously enough of the testosterone. Effect in women in general. So, so to me, I find it somewhat low-hanging fruit. When I've got a young woman, I'll take myself as a great example, right? Very young when her ovaries were removed, chemotherapy, but then ovaries were removed in her early 30s. I don't know what my average testosterone level was when when I was in my 30s, but my guess is it wasn't four. Okay. And so consistently Brookes vaughan: Yeah, yeah, much higher. Dr. Corinne Menn: when I checked Brookes vaughan: Mm-hmm. Dr. Corinne Menn: Total serum testosterone levels, which we know they're not perfect. There's lots of issues with, testing testosterone levels and getting a super accurate. But I can tell you mine were in an extremely, extremely low range, right? Number Brookes vaughan: Yeah. Dr. Corinne Menn: one. And I did have very low libido and my sexual function was impacted for lots of reasons, right? but using the data from Women with hypoactive sexual desire disorder and the global position statement on how we can give testosterone. I was prescribed that in a low, 1% testosterone, gel for men, a pea-sized amount, the tube lasts you 10 days, recheck your labs in six to eight weeks. And so testosterone like went from like four to like it hovers between like 25 and 38. So, and I watched that. make sure and I did an ultrasensitive estradiol to that where it's not converting to high levels of estrogen. So and you could do that as a trial for three to six months without Brookes vaughan: Mm-hmm. Dr. Corinne Menn: systemic estrogen. And it's actually not that scary. And so what some women might, you know, in my experience it helped me a lot. I felt that from an HSDD, those parameters as well as just sexual function, arousal, etc, that all improved a lot. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: many, many women will tell me they feel other things too. And, Brookes vaughan: Mm-hmm. Dr. Corinne Menn: you know, we can debate online about whether it makes them feel Brookes vaughan: Mm-hmm. Dr. Corinne Menn: less brain fog or more, more peppy, or more alert, or where I understand the data is mixed out there, but I there is no data that's definitive that it's not. And I have enough patients who I trust how they feel say they feel better. Okay. Brookes vaughan: Better. Dr. Corinne Menn: Now we have a long way to go with. clarifying that. And there's those are actually comp, I think they're complicated studies too because trying to nail down feeling like myself again, feeling sharper, how do you quantify that? It's not Brookes vaughan: Yeah. Can't quantify it. Dr. Corinne Menn: easy. Yeah, yeah. Not easy. But I think it's reasonable to try that. Now, who I would be cautious with. So in a testosterone setting, like if you're like putting aside systemic estrogen and you're trying to be very like cautious about that again. You can follow their levels, you can follow their labs and Brookes vaughan: Right. Dr. Corinne Menn: keep an eye on how you're feeling. and you know, if you know, and this is a conversation, you know, listen, the medical oncologists, they say, listen, if we're keeping estradiol levels low and we're keeping testosterone in a lower or medium range, do you know, is is are you okay with that? Are you comfortable with that? And I and I think we share decision making. I think a lot of medical oncologists are okay. And listen, after Brookes vaughan: Mm-hmm. Dr. Corinne Menn: six or seven months, if the patient's like, yeah, like I. I this hasn't touched me at all. There's really no benefit. We've gone up a little bit. Then we then we stop. It's a trial. It's a trial. But for the patients Brookes vaughan: Mm-hmm. Mm-hmm. Mm-hmm. Dr. Corinne Menn: who it's helped them, it's really, really helped them, in my opinion. Now, Brookes vaughan: Yeah. Yeah. Dr. Corinne Menn: there's some data that triple negative patients, that they're they might over there's a a proportion of those patients that might overexpress the androgen receptor, and that could lead to a more negative impact that like stimulating Brookes vaughan: Mm-hmm. Dr. Corinne Menn: that androgen receptor is negative. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: The opposite seems to be the signal with ER positive that 85% of those patients actually do express an androgen receptor and stimulating that is actually protective. But again, this is very early preliminary data. But I all I know is that I have lots of ER positive patients and nobody ever checks their testosterone. And many of these women never have their ovaries removed and their testosterone levels are not four. And maybe when we have a patient who's presenting. With symptoms and we can keep it in a measured way. there are some, you know, prospective observational data that's been published out of UK and others where women who were breast cancer survivors did improve menopause specific quality of life domains, even outside of sexual function, improved. So to me, I think it's in the big scheme of things where we we can want more perfect data and we can demand more perfect data. But women right now can't always wait for perfect data. So if we have something available that we can try that is reasonable, I think they they should be able to have access to that without feeling Brookes vaughan: that conversation. Dr. Corinne Menn: like a pariah for asking for it. It's not that unreasonable. And I always come Brookes vaughan: Right. Dr. Corinne Menn: back. We let you be pumped with IVF medications and be pregnant because we value Brookes vaughan: Yeah. Yeah. Dr. Corinne Menn: fertility after breast cancer. Brookes vaughan: Yeah. Dr. Corinne Menn: But God forbid, with an early stage patient with a low risk of recurrence who wants to use a little bit of testosterone, or consider with full informed consent that to use an estrogen patch and progesterone, a low dose, see how she feels, give it a trial because she's exhausted her other options that haven't worked for her. Why is that so bad? That's how that's how I think about it. And and Brookes vaughan: Mhm. Yeah, yeah, for sure. Agree. Dr. Corinne Menn: and with these patients, whether it's testosterone or systemic estrogen. I see them frequently. I we always reevaluate, say, step back. How are you feeling about this? How would you feel if there was a recurrence? How is your, do we ever want to explore, hey, there's a new non-hormonal? I always circle back to our full toolkit. Yeah. Brookes vaughan: Full picture. Mm-hmm. Dr. Corinne Menn: And trust me, for every patient who comes to find tries to seek me out for care and they want to get hormones after breast cancer, for Brookes vaughan: Mm-hmm. Dr. Corinne Menn: every one of them or for all those patients, probably only a small percentage of them will actually. wind up going onto symbolic hormonal therapy because when they get to me, I am always really horrified that all of the basic tools have not been done. The endocrine Brookes vaughan: Yeah. Dr. Corinne Menn: therapy hasn't been individualized. No one's talked to them about VOs or LinkUnit or the nonhormonals. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: No one's optimized their vaginal hormones. No Brookes vaughan: Yeah. Dr. Corinne Menn: one's talked to them about really being able to use lifestyle medicine in a way that can be really beneficial. There's Brookes vaughan: Mm-hmm. Dr. Corinne Menn: so much that's been missing there. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: So my thing is do women all do breast cancer survivors all want HRT after breast cancer? The answer's no. They Brookes vaughan: Yeah. Dr. Corinne Menn: just want you to take them seriously and individualize their menopause care. And it's not happening because nobody has the time or the knowledge base to truly give it to them. Brookes vaughan: Yeah. That's so true. That's so true. And talk to me, let's talk a little bit about vaginal estrogen. Say you I think I've heard you say if you were diagnosed with breast cancer today, you would start Dr. Corinne Menn: Yeah. Brookes vaughan: vaginal estrogen right away. Is that Dr. Corinne Menn: Yeah. if I was, if I knew that my breast cancer treatment was going to start to put me into menopause, then absolutely I would. Brookes vaughan: To pet you in Dr. Corinne Menn: yeah, because what I've seen is years of chronic progressive genitourinary syndrome of menopause, vulvar vaginal atrophy, clitoral atrophy, chronic UTIs, and it's needless suffering. And you and I have seen, I know that it's We could always treat and we could reverse most of GSM, but Brookes vaughan: Just Dr. Corinne Menn: it can take longer to do. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: And I think if we use we can use very small amounts up front to protect and prevent rather than try to play catch-up two, three, four, eight, ten years down the road. And that's what we see in our practices. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: and so you can use less hormones if you would just treat them up front. Brookes vaughan: Friend. Dr. Corinne Menn: I think it's foolish to tell a 34-year-old who you're gonna put on luprin for a decade. So an ovarian function suppression for a decade, and you're gonna give her an aromatase inhibitor, or you might remove her ovaries. So you're starving her genital urinary tract of androgens and estrogen, Brookes vaughan: Change. Dr. Corinne Menn: right? You're starving it. I don't all the coconut oil in the world is not going to Brookes vaughan: Right. Dr. Corinne Menn: prevent what's gonna happen. It can help. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: The lubricants can help, but they're not actually treating Brookes vaughan: We're not enough. Dr. Corinne Menn: the problem. And so when we tell women, do that first, fail, which I can promise you, you will fail. It will. Now, we'll, Brookes vaughan: Yeah. It will. Mm-hmm. Mm-hmm. Dr. Corinne Menn: it doesn't fail everybody who has maybe just natural menopause or a woman who's on, say, tamoxifen and she's still getting her her you know her periods. But I have yet to find a case where someone has. Ovarian functions, suppression, they've lost their ovaries and they're on an aromatase inhibitor. At some point in their time, they're gonna have progressive GSM. Moisturizer and lubricants will not prevent the changes. I don't know what you tell me. Brookes vaughan: That's right. That's right. Yeah. Dr. Corinne Menn: So why are we kicking the can down the road? Right. so that's Brookes vaughan: Mm-hmm. Mm-hmm. Dr. Corinne Menn: and and I I relate it back to pre medication. So they pre medicated me so I can handle chemo. So I wasn't nauseous. They, you know, they gave you all sorts of medications to keep your, you know, your your white blood counts up and et cetera, right? this is pre-medication so that you can weather a decade Brookes vaughan: Mm-hmm. Dr. Corinne Menn: of breast cancer treatment. Brookes vaughan: Yeah. Yeah. Yeah. Exactly. And I think even to this day, even without the black box warning, people think, my gosh, I can't estrogen. Th w there's gonna be some systemic absorption and it's gonna be ne but it does not. It does not increase the risk of breath cancer at all. Dr. Corinne Menn: Okay. No, and also in and listen, and I understand that someone might say, like, well, what about these aromatis inhibitor patients? These are the patients who get the most like pushback because the whole point is that we're trying to keep their estrogen levels zero, right? Brookes vaughan: Everything. Yeah. Dr. Corinne Menn: So so fine. So those are exactly the patients. Don't wait until their tissue is so thin and they're desperate, and then make them use it then because that's when the estrogen is more at risk for having a higher absorption. And there's ways that we can We can give vaginal estrogen if we want to be extremely cautious. So, a great example is, you know, don't dump two grams of estrogen at the top of a very atrophic vagina with estrogen cream, but it doesn't mean you can't use cream because I think that's really effective for these patients. You Brookes vaughan: Yeah. Dr. Corinne Menn: can kind of target it at the lower one third. They probably only need a half a gram in the Brookes vaughan: Mm-hmm. Mm-hmm. Dr. Corinne Menn: lower third and then on the outside or. Use something low like the lowest invexy four micrograms twice a week for prevention on the inside, Brookes vaughan: Mm-hmm. Dr. Corinne Menn: and then apply, vaginal estradiol, or consider using intrarosa, which is hitting both androgen and estrogen receptors. Start that early. Maybe you don't even need intarosa every day in that case. You might be able to use it maybe three or five times a week. Brookes vaughan: Yeah. Dr. Corinne Menn: what we can modify the way we give these if we want to be quote unquote extra cautious. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: I think that they can all be given standard of way they're written, but but we can modify them, Brookes vaughan: That's right. Dr. Corinne Menn: I think it is the medical oncologist's job here to lower the fears here because their patients are looking to them for permission. and so I can say everything I want, but until I have my oncology colleagues supporting the message, informing patients and reinforcing that message, and not making them fear, so Brookes vaughan: Mm-hmm. Dr. Corinne Menn: much. I think, if we could just solve that, we would Brookes vaughan: Yeah. Dr. Corinne Menn: we would alleviate so much suffering. We would alleviate so much suffering, right? Yeah. Brookes vaughan: Yeah. So much suffering. That's right. That's right. And it is really fat. We have an incredible medical oncology team here and we share patients and it has been very encouraging to see the labs that they're Dr. Corinne Menn: sí. Brookes vaughan: checking. And it it's not always gonna be perfect because they don't have the time. There's you know, they're seeing so many patients. But Dr. Corinne Menn: No. Brookes vaughan: we had one recently who had a history of DCIS, double mastectomy, stage zero. Dr. Corinne Menn: Zim. Brookes vaughan: not on, any sort of hormone blockers, aromatase inhibitors, Dr. Corinne Menn: So Brookes vaughan: anything. And her oncologist here was like, Hey, you are suffering Dr. Corinne Menn: Yeah, simple. Brookes vaughan: with these, you know, symptoms of menopause and perimenopause. Why not? Why not let's consider a small dose of a an estradiol patch, Dr. Corinne Menn: So Brookes vaughan: a little project you know, and so it is encouraging that I feel like the conversation is moving. Dr. Corinne Menn: It's moving. It is. It is. And there's no such thing in life as no risk. There's risks Brookes vaughan: That's right. Dr. Corinne Menn: to doing things. And sometimes there's risks to not doing things, you know? and yeah, and I think Brookes vaughan: That right. Yeah. Talk about that. Because that's a big Dr. Corinne Menn: and I think that's really important, you know, and like you you a a case, a DCIS patient who had no invasive disease, and they don't all choose bilateral mastectomies, most don't, but there is a proportion, a significant proportion who do. Blocking their hormones aren't is never part of their treatment. If you have a bilateral mastectomy after DCAS, we don't stop your periods if you're still getting them. You may go on for a decade. I know many, Brookes vaughan: That's right. Dr. Corinne Menn: many patients in that scenario. And then when they get to menopause, suddenly hormones are evil. Come on, it doesn't make any sense. And those Brookes vaughan: Yeah. Yeah. That's right. Dr. Corinne Menn: patients always know, even previvors who have risk reducing mastectomies. I always tell them, even though you had your breast removed, you still can get. Breast cancer. It's extremely rare. Is Brookes vaughan: Mm-hmm. Dr. Corinne Menn: it a zero chance? No, because there's always theoretical that you've left a cell behind. there's Brookes vaughan: Mm-hmm. Dr. Corinne Menn: some cells that are left behind, right? but it's exceedingly rare and uncommon, and hence why we treat you differently, you know, and should be able to have choice. So to me, you've you've already brought some of them up. So, like the DCAS patients, those with bilateral mastectomies after DCIS. I think our triple negative patients are like the a a very ripe population that we should really be considering some some real controlled studies on whether or not because once they're out of their higher risk window of recurrence, which is the first four to five years, their risk of getting that breast cancer recurred is extremely low. Some of them might be genetic carriers of a BRC mutation or something else, where they are at higher risk of another new breast cancer. Brookes vaughan: Mm-hmm. Mm-hmm. Dr. Corinne Menn: That's a separate conversation. but and even in those cases, they tend to have had a bilateral mastectomy Brookes vaughan: Yeah. Dr. Corinne Menn: then. So I think those patients are kind of again low-hanging fruit of where it makes a little bit more common sense. And Brookes vaughan: Mm-hmm. Yeah. Dr. Corinne Menn: then we then we put it in another bucket, the higher risk of recurrence, strongly estrogen receptor positive, and then we have to manage those patients with a lot of nuance, right? Brookes vaughan: That's right. That's Dr. Corinne Menn: and also trying something. For a short period of time, Brookes vaughan: Mm-hmm. Mm-hmm. Dr. Corinne Menn: sometimes also gives us information. So I've had breast cancer Brookes vaughan: Yeah. Dr. Corinne Menn: survivors who have made a decision to want to try, I'd say a low dose, estrogen, or progesterone, just to see how they feel. And if it's totally improved their quality of life and this Brookes vaughan: Mm-hmm. Dr. Corinne Menn: has changed their life, that's part of their decision. So it's okay to say, like, we're gonna try something for three months, reassess. Is this worth? Do you feel comfortable doing this? How is this working for you? Right. Brookes vaughan: Right. Mm-hmm. Dr. Corinne Menn: And then some of those patients are the ones who, if they're like, you know what, I really think I want to stay on this, that's when I might encourage them. Maybe for the longer term, I might want to switch you to do a V because Brookes vaughan: Yeah. Dr. Corinne Menn: due a V has theoretically interesting breast safety Brookes vaughan: Yeah. Dr. Corinne Menn: aspects, which we're hoping there is some studies that are ongoing in high risk populations, not in invasive cancer, but in high risk populations Brookes vaughan: Mm-hmm. Dr. Corinne Menn: for getting breast cancer. using do a bee to see if it actually lowers the risk. So I Brookes vaughan: Wow. Dr. Corinne Menn: I I think we're gonna hear about some of that those data hopefully in the next year or so. Right. So I think we are we're moving in the direction. Brookes vaughan: We're getting there, that's right. Talk about you alluded a little bit to BRACA, BRCA1, BRCA2. Tell me, Dr. Corinne Menn: Yeah, so Brookes vaughan: and I would love to know sort of your elevator pitch for you. Someone says to you, well, Dr. Corinne Menn: Sense we Brookes vaughan: menopause hormone therapy, MHT, HRT, causes breast cancer. So what how do you, in an elevator, how would you address that? Because we hear Dr. Corinne Menn: Yeah. Yeah. Brookes vaughan: that all the time. Dr. Corinne Menn: Yeah. So there's no study that's ever said or shown that HRT causes breast cancer. And the largest randomized controlled study that was the most expensive and the most comprehensive actually showed us how safe systemic estrogen is because in the WHI study Estrogen alone lowered breast cancer risk. And I'm not going to say, and that was conjugated equine estrogen. And so that's what we can say about conjugated equine estrogen. And in smaller, not all randomized controlled studies, the similar findings were found for estradiol. We have stronger evidence for conjugated equine estrogen, but like, so that's why we say estrogens in general don't cause it. And then I just remind patients that increasing a risk or an association is not the same as causing. And I think people get hung up on ER positive breast cancer. And so I always come remind patients that if you are diagnosed or somebody in your family who is diagnosed with ER positive breast cancer, many patients are led to believe that that means that estrogen caused their breast cancer. And I like to point out that the men in your life have estrogen receptors on their breasts. every cell in your body has an estrogen receptor, so it just means that. Those cancer cells turned malignant because of when cells are dividing and turning over, they make errors, they can have mutations. And then when that can when that cell becomes a cancerous cell, it manipulates the estrogen receptors. So they use the estrogen receptors as a way to help it grow. That's extremely different than telling somebody that estrogen causes breast cancer. So when Brookes vaughan: Press cancer. Dr. Corinne Menn: you understand that, you could understand. If you have cells that are overexpressing estrogen receptors, we're going to target treatment. Brookes vaughan: Mm-hmm. Dr. Corinne Menn: One of the many ways is by starving that cell of estrogen or blocking those receptors. But it doesn't mean that estrogen caused that to grow or cause it to come into being, right? Brookes vaughan: Mm-hmm. Dr. Corinne Menn: so I think that's really important. and you know what I love is that we actually have really, really good data in our BA BRCA. Positive breast cancer patients are breast cancer previvors who carry a genetic predisposition. I think it's really fascinating data because we know that when we remove these women's ovaries, we lower their risk of ovarian cancer and we lower their risk of breast cancer. But time after time, study after study has shown that when we give them back estrogen, we don't negate the lowering of their ovarian cancer risk, obviously, because the ovaries are gone. But we also don't negate the lowering of their breast cancer risk. So it tells Brookes vaughan: Okay. Dr. Corinne Menn: you it's a lot more than what we think it is, right? So BROCA carriers can have back Brookes vaughan: Mm-hmm. Dr. Corinne Menn: HRT. And I call HRT in this case because these women are generally under the age of 51 when they Brookes vaughan: Great, yes. Dr. Corinne Menn: get their ovaries. This is premature menopause. They need full hormone replacement therapy up until the age of natural menopause. Brookes vaughan: Yeah. Dr. Corinne Menn: And that's NCCN guidelines. It's not a fringe opinion, right? Brookes vaughan: Mm-hmm. That's right. Dr. Corinne Menn: And then the one thing I want to squeak in here is this idea that estrogen causes breast cancer. So I think we have a lot of messages out there that perpetuate that. We ask women how old were they when they got their periods? How old were they when they went through menopause? How many children did they have? How much lifetime estrogen exposure? And so we oversimplify it and we say it's estrogen exposure equals breast cancer. we also kind of throw this in when we talk about. Weight, obesity, and alcohol use, we say, those things increase breast cancer risk because it causes your body to make more estrogen. And I think it's it's like an overly simplistic and I think an ignorant way to talk about it. What is actually happening is that when you have every time you have a menstrual cycle, an ovulation, your breast is changing. Your breast is not static tissue. So when you start ovulation when a young Younger woman, your breast then has grown. There's more chances of in that menstrual cycle every month with the growth of the ducts and the lobules, and then it regresses and growth, proliferation back and forth. Cells change, cells grow. It's every time that happens, is a chance for a mutation to happen, right? And so And it's it and we understand that when ovari we talk about this with ovarian cancer, right? Women on birth control pills don't ovulate, so they don't have as many chances, we think is part of why we're lowering their ovarian cancer risk. So I think it's a little bit, it's a lot more nuanced than just the estrogen exposure caused it. Because what's interesting, we overload women with estrogen in pregnancy. It's like huge amounts, but what happens to their breast? Brookes vaughan: That's right. Dr. Corinne Menn: Tissue is the mature and at the end, like towards the end of pregnancy, and then through breastfeeding, it they're they're kind of stable. They're mature and grown. And then during that, so we know pregnancy and breastfeeding is very protective, right? Brookes vaughan: Yeah. Dr. Corinne Menn: And then right when you stop breastfeeding and the breast starts to change and you know go back, that involution of your breast tissue. That's a time, a higher little window, a window of breast cancer risk. Why? Because there's a lot of changes happening. So you gotta think of these changes and it's a dynamic Brookes vaughan: Changes, yes. Hmm. Dr. Corinne Menn: environment. And when we just simplify it as oestrogen bad, and we're like, how about the dynamics of what your breast tissue is exposed to and changing over a lifetime? Brookes vaughan: Mm-hmm. Dr. Corinne Menn: That is what the real question is, right? And so I. I think, I so, while I like these risk calculators, I do think the risk calculators do make people a little scared of their own yes. Brookes vaughan: That's right. That yeah, yeah, that makes sense. And you said earlier, you alluded to there's a risk with everything. There's a risk with doing something. There can, you know, there can be a risk with doing something, but there can also be a risk to not doing something. And Dr. Corinne Menn: Two more automated set. Yes. Brookes vaughan: that is something that we, you know, we don't talk a lot. I think a lot of times even previvors, Dr. Corinne Menn: Even Brookes vaughan: survivors are left out of this metabolic conversation, you know, of Dr. Corinne Menn: Yes. Yes. See Brookes vaughan: insulin resistance incre we've seen this time and time again with we see it in perimenopause and menopause, but we also see it in survivors Dr. Corinne Menn: it in people seeing. Brookes vaughan: and and in even previvors who are their hormones are blocked and we start to see L DL cholesterol go up. We start to see insulin resistance increase. And and so you know, there obviously there are other things you can do aside from Dr. Corinne Menn: It's Brookes vaughan: HRT for those patients. You know, you can Obviously modify with diet and exercise and even GLP ones. We we won't get into that today, but that is a really interesting thing that we're seeing Dr. Corinne Menn: I think so too. Absolutely. Brookes vaughan: as a life changing option. Dr. Corinne Menn: Yes. A hundred percent. A Brookes vaughan: Do you see that in a lot of your patients? Yeah. Dr. Corinne Menn: hundred percent. I think you know, lifestyle medicine as a prescription, Brookes vaughan: Mm-hmm. Dr. Corinne Menn: responsible, appropriate, targeted, well-monitored at GLP1 use, along with strength training. Brookes vaughan: Yes. Same fine. Dr. Corinne Menn: And because breast cancer survivors are at risk for osteoporosis at baseline. They're at risk for muscle loss at baseline. So we want to be careful with the GLP ones in that realm. But Brookes vaughan: Yes. Dr. Corinne Menn: I have found with good support, it could be really life-changing. And the the the bottom line is we have to we have to be utilizing the lifestyle pillars in in profound ways that we are not. Brookes vaughan: thank you. This was great. This was so informative. Dr. Corinne Menn: Well well, thank you for your work. Brookes vaughan: Keep doing what you're doing. I really appreciate it. Thank you. Dr. Corinne Menn: Thank you for your work. And and the message to your audience is that we have a full toolkit and you are not alone and you are Brookes vaughan: Yeah. That's right. Dr. Corinne Menn: worth being a squeaky wheel and speaking up and demanding better Brookes vaughan: Yes. Dr. Corinne Menn: care. Brookes vaughan: And you can feel good again. You can. You can feel well. You can feel like yourself. Yeah. Dr. Corinne Menn: You can feel good again. Yes. Even if even if you don't choose or ever get access to systemic estrogen, you can still feel really well, but you Brookes vaughan: That's right. That's right. Dr. Corinne Menn: can you should still be able to have a choice on how you live. Thank you so much. Thank you Brookes vaughan: That's right. I completely agree. Completely. Well, Doctor Mann, thank you so much.